{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:42:27Z","timestamp":1777934547976,"version":"3.51.4"},"reference-count":10,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate which combine trastuzumab (T), a monoclonal antibody targeting the human epidermal growth factor receptor-2 (HER2), and a cytotoxic molecule derived from maytansine (DM1).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>We report the first case of T-DM1-associated pleural and pericardial effusions three weeks after the second course of T-DM1 in a patient with breast cancer. Drug-induced pleural and pericardial effusions was implicated in the absence of other etiologies. The Naranjo Scale indicated a probable drug-induced adverse reaction. Management &amp; outcome: The patient fully recovered after thoracentesis and discontinuation of T-DM1. The patient has reported no side effect after the sixth course of trastuzumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>To our knowledge, this is the first case in the literature of bilateral pleural and pericardial effusions in a patient treated with T-DM1. The successful initiation of treatment with trastuzumab following withdrawal of T-DM1 suggests that emtansine played a role in the development of bilateral pleural and pericardial effusions. We hypothesize that the patient\u2019s condition was a result of a local inflammatory reaction to emtansine by direct toxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552211015772","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T03:44:52Z","timestamp":1621309492000},"page":"2041-2044","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Trastuzumab-emtansine induced pleural and pericardial effusions"],"prefix":"10.1177","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6619-8839","authenticated-orcid":false,"given":"Jeffrey","family":"Lombardi","sequence":"first","affiliation":[{"name":"Pharmacy Department, Centre Georges-Fran\u00e7ois Leclerc, Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Lory","sequence":"additional","affiliation":[{"name":"Regional Pharmacovigilance Centre of Burgundy, University Hospital of Dijon, Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"Martin","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Centre Georges-Fran\u00e7ois Leclerc, Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Mayeur","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Centre Georges-Fran\u00e7ois Leclerc, Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Combret","sequence":"additional","affiliation":[{"name":"Regional Pharmacovigilance Centre of Burgundy, University Hospital of Dijon, Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Grandvuillemin","sequence":"additional","affiliation":[{"name":"Regional Pharmacovigilance Centre of Burgundy, University Hospital of Dijon, Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charl\u00e8ne","family":"Boulay","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Centre of Rouen, University Hospital of Rouen, Rouen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3132-7730","authenticated-orcid":false,"given":"Antonin","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Centre Georges-Fran\u00e7ois Leclerc, Dijon, France"},{"name":"INSERM U1231, University of Burgundy Franche-Comt\u00e9, Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,5,18]]},"reference":[{"key":"bibr1-10781552211015772","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3621"},{"key":"bibr2-10781552211015772","unstructured":"Has-sant\u00e9.fr [website], www.has-sante.fr\/jcms\/c_1735595\/fr\/kadcyla-trastuzumab-emtansine-anticorps-ciblant-le-recepteur-her-2-couple-a-un-cytotoxique (accessed 13 November 2020)."},{"key":"bibr3-10781552211015772","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr4-10781552211015772","unstructured":"Product Information: KADCYLA\u00ae intravenous injection, ado-trastuzumab emtansine intravenous injection. South San Francisco, CA: Genentech Inc (per FDA), 2019."},{"key":"bibr5-10781552211015772","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1215"},{"key":"bibr6-10781552211015772","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.01.120"},{"key":"bibr7-10781552211015772","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.13.300"},{"key":"bibr8-10781552211015772","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.635144"},{"key":"bibr9-10781552211015772","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2828(03)00145-7"},{"key":"bibr10-10781552211015772","doi-asserted-by":"publisher","DOI":"10.1177\/1078155218813716"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211015772","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552211015772","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211015772","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:24:54Z","timestamp":1777688694000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552211015772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,18]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1177\/10781552211015772"],"URL":"https:\/\/doi.org\/10.1177\/10781552211015772","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,18]]}}}